[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","commit":"28a6975696","date":"2026-09-10","author":"Jude Gomila","message":"Tone pass: solution and mechanism first; frightening figures behind a click","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"history","before":"[\n      { year: 1987, title: \"Slamon links HER2 amplification to poor prognosis\" },\n      { year: 1998, title: \"Trastuzumab approved\", refs: [\"trastuzumab\"] },\n      { year: 2013, title: \"First solid-tumour ADC: T-DM1...","after":"[\n      { year: 1987, title: \"Slamon shows HER2 amplification marks aggressive disease, and a drug target\" },\n      { year: 1998, title: \"Trastuzumab approved\", refs: [\"trastuzumab\"] },\n      { year: 2013, title: \"Fir..."}]},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"tldr","before":"\"Once the most aggressive subtype, now one of the most treatable thanks to trastuzumab and, more recently, Enhertu.\"","after":"\"HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu.\""}]},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/","commit":"cebb34a709","date":"2026-09-08","author":"Jude Gomila","message":"Guideline mapping on every standard-of-care row; sourced biomarker prevalence for 59 targets; GuidelineChip, PrevalenceTable, CancerPrevalen","file":"src/data/cancers.ts","type":"changed","fields":[{"field":"standardOfCare","before":"[\n      { setting: \"Early stage\", approach: \"Neoadjuvant THP or T-DXd → surgery → trastuzumab/pertuzumab (pCR) or T-DXd/T-DM1 (residual).\", refs: [\"trastuzumab\", \"trastuzumab-deruxtecan\", \"trastuzumab-emtansine\", \"des...","after":"[\n      { setting: \"Early stage\", approach: \"Neoadjuvant THP or T-DXd → surgery → trastuzumab/pertuzumab (pCR) or T-DXd/T-DM1 (residual).\", refs: [\"trastuzumab\", \"trastuzumab-deruxtecan\", \"trastuzumab-emtansine\", \"des..."}]}]